Skip to main content
Erschienen in: International Journal of Hematology 3/2023

01.07.2023 | Original Article

Treatment of new-onset primary central nervous system lymphoma in elderly patients using RMPV chemotherapy: a single-institution experience

verfasst von: Michiharu Yoshida, Takeharu Kato, Takeshi Hiu, Yoshitaka Imaizumi, Simpei Morimoto, Daisuke Niino, Susumu Yamaguchi, Shiro Baba, Kenta Ujifuku, Koichi Yoshida, Ayaka Matsuo, Yoichi Morofuji, Tsuyoshi Izumo, Shinji Okano, Yasushi Miyazaki, Takayuki Matsuo

Erschienen in: International Journal of Hematology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

The prognosis of primary central nervous system lymphoma (PCNSL) in the elderly remains poor. We aimed to evaluate the outcome of rituximab, methotrexate, procarbazine, and vincristine (RMPV) chemotherapy in elderly patients with new-onset PCNSL. Twenty-eight patients aged ≥ 70 years treated for PCNSL between 2010 and 2020 were examined retrospectively. Nineteen patients received RMPV and nine did not qualify. Patients received five to seven cycles of RMPV plus response-adapted whole-brain radiotherapy (WBRT) and cytarabine. Ten of the 19 patients who received RMPV (52.6%) completed the induction, but only four patients (21.1%) completed RMPV chemotherapy, WBRT 23.4 Gy, and cytarabine. Median progression-free survival (PFS) and overall survival (OS) in the RMPV group was 54.4 and 85.0 months, respectively. Both PFS and OS were significantly longer in patients who received RMPV chemotherapy than in those who did not, and in patients who started but did not complete RMPV than in those who did not receive RMPV. Patients who received incomplete RMPV tended to have a favorable prognosis. Initial treatment with RMPV chemotherapy was effective in elderly patients with PCNSL. Adjusting the number of courses of RMPV may improve the prognosis of elderly patients with PCNSL, but further verification is necessary.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat van der Meulen M, et al. Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989–2015. Leukemia. 2017;31(8):1822–5.CrossRefPubMed van der Meulen M, et al. Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989–2015. Leukemia. 2017;31(8):1822–5.CrossRefPubMed
2.
3.
Zurück zum Zitat Eloranta S, et al. Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000–2013. Eur J Haematol. 2018;100(1):61–8.CrossRefPubMed Eloranta S, et al. Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000–2013. Eur J Haematol. 2018;100(1):61–8.CrossRefPubMed
4.
Zurück zum Zitat Kasenda B, et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)–a systematic review and individual patient data meta-analysis. Ann Oncol. 2015;26(7):1305–13.CrossRefPubMedPubMedCentral Kasenda B, et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)–a systematic review and individual patient data meta-analysis. Ann Oncol. 2015;26(7):1305–13.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Mendez JS, et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol. 2018;20(5):687–94.CrossRefPubMed Mendez JS, et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol. 2018;20(5):687–94.CrossRefPubMed
6.
Zurück zum Zitat van der Meulen M, et al. Primary therapy and survival in patients aged over 70-years-old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands. Haematologica. 2021;106(2):597–600.CrossRefPubMed van der Meulen M, et al. Primary therapy and survival in patients aged over 70-years-old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands. Haematologica. 2021;106(2):597–600.CrossRefPubMed
7.
Zurück zum Zitat Morris PG, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971–9.CrossRefPubMedPubMedCentral Morris PG, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971–9.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Shah GD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25(30):4730–5.CrossRefPubMed Shah GD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25(30):4730–5.CrossRefPubMed
9.
Zurück zum Zitat Abrey LE, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034–43.CrossRefPubMed Abrey LE, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034–43.CrossRefPubMed
10.
Zurück zum Zitat Abrey LE, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24(36):5711–5.CrossRefPubMed Abrey LE, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24(36):5711–5.CrossRefPubMed
11.
Zurück zum Zitat Laack NN, et al. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96–73-51. Int J Radiat Oncol Biol Phys. 2006;65(5):1429–39.CrossRefPubMed Laack NN, et al. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96–73-51. Int J Radiat Oncol Biol Phys. 2006;65(5):1429–39.CrossRefPubMed
13.
Zurück zum Zitat Roth P, et al. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology. 2012;79(9):890–6.CrossRefPubMed Roth P, et al. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology. 2012;79(9):890–6.CrossRefPubMed
14.
Zurück zum Zitat Schmitt AM, et al. Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis. Hematol Oncol. 2019;37(5):548–57.CrossRefPubMed Schmitt AM, et al. Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis. Hematol Oncol. 2019;37(5):548–57.CrossRefPubMed
15.
Zurück zum Zitat Fritsch K, et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol. 2011;22(9):2080–5.CrossRefPubMed Fritsch K, et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol. 2011;22(9):2080–5.CrossRefPubMed
16.
17.
Zurück zum Zitat Houillier C, et al. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. J Neurooncol. 2017;133(2):315–20.CrossRefPubMed Houillier C, et al. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. J Neurooncol. 2017;133(2):315–20.CrossRefPubMed
18.
Zurück zum Zitat Makino K, et al. Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience. Int J Clin Oncol. 2015;20(1):29–34.CrossRefPubMed Makino K, et al. Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience. Int J Clin Oncol. 2015;20(1):29–34.CrossRefPubMed
19.
Zurück zum Zitat Schorb E, et al. High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study. Blood Adv. 2020;4(14):3378–81.CrossRefPubMedPubMedCentral Schorb E, et al. High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study. Blood Adv. 2020;4(14):3378–81.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Bairey O, Siegal T. The possible role of maintenance treatment for primary central nervous system lymphoma. Blood Rev. 2018;32(5):378–86.CrossRefPubMed Bairey O, Siegal T. The possible role of maintenance treatment for primary central nervous system lymphoma. Blood Rev. 2018;32(5):378–86.CrossRefPubMed
21.
Zurück zum Zitat Vu K, et al. Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma. Br J Haematol. 2019;186(1):180–3.CrossRefPubMedPubMedCentral Vu K, et al. Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma. Br J Haematol. 2019;186(1):180–3.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Grommes C, et al. Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro Oncol. 2019;21(3):306–13.CrossRefPubMed Grommes C, et al. Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro Oncol. 2019;21(3):306–13.CrossRefPubMed
23.
Zurück zum Zitat Narita, Y., et al., Phase 1/2 Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Relapsed/Refractory Primary Central Nervous System Lymphoma. Neuro Oncol, 2020. Narita, Y., et al., Phase 1/2 Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Relapsed/Refractory Primary Central Nervous System Lymphoma. Neuro Oncol, 2020.
Metadaten
Titel
Treatment of new-onset primary central nervous system lymphoma in elderly patients using RMPV chemotherapy: a single-institution experience
verfasst von
Michiharu Yoshida
Takeharu Kato
Takeshi Hiu
Yoshitaka Imaizumi
Simpei Morimoto
Daisuke Niino
Susumu Yamaguchi
Shiro Baba
Kenta Ujifuku
Koichi Yoshida
Ayaka Matsuo
Yoichi Morofuji
Tsuyoshi Izumo
Shinji Okano
Yasushi Miyazaki
Takayuki Matsuo
Publikationsdatum
01.07.2023
Verlag
Springer Nature Singapore
Erschienen in
International Journal of Hematology / Ausgabe 3/2023
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-023-03632-9

Weitere Artikel der Ausgabe 3/2023

International Journal of Hematology 3/2023 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.